Literature DB >> 6736206

Relationship between plasma aldosterone and angiotensin II before and after noradrenergic inhibition in normal subjects and patients with mild essential hypertension.

C Beretta-Piccoli, P Weidmann, K Boehringer, L Link, M G Bianchetti, J J Morton.   

Abstract

The responsiveness of plasma aldosterone to the infusion of angiotensin II at dose rates of 2, 4, and 10 ng/kg X min was assessed in 11 normal subjects and 13 patients with mild essential hypertension before and after 4 weeks of treatment with the sympatholytic agent debrisoquine. Debrisoquine treatment caused a significant (P less than 0.01) decrease in circulating norepinephrine (-45%), but did not modify plasma levels of angiotensin II, renin, aldosterone, or epinephrine or the metabolism of sodium or potassium. In normal subjects, debrisoquine caused a significant shift to the left (P less than 0.05) of the correlation relating plasma aldosterone to plasma angiotensin II levels. In patients with essential hypertension, the aldosterone-angiotensin II interrelationship was not modified. These findings suggest that the sympathetic nervous system exerts an inhibitory influence on aldosterone responsiveness to angiotensin II in normal man, and that this physiological interaction is impaired in patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6736206     DOI: 10.1210/jcem-59-2-316

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  Ketanserin in the treatment of diabetes-associated hypertension.

Authors:  C Beretta-Piccoli
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Hyperreninemic hypoaldosteronism after chronic stress in the rat.

Authors:  G Aguilera; A Kiss; B Sunar-Akbasak
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

3.  A semi-physiologically based pharmacokinetic pharmacodynamic model for glycyrrhizin-induced pseudoaldosteronism and prediction of the dose limit causing hypokalemia in a virtual elderly population.

Authors:  Ruijuan Xu; Xiaoquan Liu; Jin Yang
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.